ABAXIS Announces Co-Promotion Agreement With Synbiotics Corporation

Name	Symbol	Market	Type
ALPS Medical Breakthroughs ETF	AMEX:SBIO	AMEX	Exchange Traded Fund

	Price Change	% Change	Price	High Price	Low Price	Open Price	Traded	Last Trade
	-0.4425	-1.28%	34.0889	34.45	34.09	34.45	1,659	21:15:00

ALPS Medical Breakthroug... (AMEX:SBIO)
Historical Stock Chart

From May 2019 to May 2024

Click Here for more ALPS Medical Breakthroug... Charts.

ABAXIS Announces Co-Promotion Agreement With Synbiotics Corporation UNION CITY, Calif., July 9 /PRNewswire-FirstCall/ -- ABAXIS, Inc. (NASDAQ:ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that it has entered into a Co-Promotion Agreement with Synbiotics Corporation (OTC:SBIO) (BULLETIN BOARD: SBIO) . The two companies are offering incentives to veterinary clinics currently utilizing both the Witness(R) HW canine heartworm antigen test and the VetScan(R) in-clinic chemistry analyzer, as well as any new customers that purchase both products during the co-promotion period. The co-promotion begins on July 12, 2004 and will be available to all qualified veterinary practices in the United States. "Synbiotics is pleased to be part of such a strong promotion that rewards current and future loyal customers of both Witness(R) HW and VetScan(R)," said Kent Luther, Vice President of Sales and Marketing at Synbiotics. "This agreement will increase the awareness and market share of Witness(R) HW through the promotion by ABAXIS' direct sales force and strong distributor alliances." "We are enthusiastic about the alliance between the VetScan(R) and Witness(R) HW product lines and believe this co-promotion will solidify customer loyalty for both companies," states Richard Schoen, Vice President of Sales and Marketing at ABAXIS. "We are proud to be partnering with a company who manufactures a complimentary product with quality and value comparable to the VetScan(R)." ABAXIS develops, manufactures and markets portable blood analysis systems for use in any patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 6.9 kilogram, portable analyzer and a series of 8-cm diameter single-use plastic disks, called rotors or reagent discs that contain all the reagents necessary to perform a fixed menu of tests. The system can be operated with minimal training and perform multiple tests on whole blood using either venous or fingerstick samples. The system provides test results in less than 14 minutes with the precision and accuracy equivalent to a clinical laboratory. For information on ABAXIS and its products, visit the Company's website at http://www.abaxis.com/. Synbiotics Corporation develops, manufactures and markets veterinary diagnostics and related products for the veterinary practice, veterinary laboratory and livestock & poultry markets worldwide. Headquartered in San Diego, California, Synbiotics develops, manufactures and distributes its products through its operations in San Diego, California, and Lyon, France. For information on Synbiotics and its products, visit the Company's website at http://www.synbiotics.com/. This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. ABAXIS claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. Specific forward-looking statements contained in this press release include, but are not limited to, risks and uncertainties related to the market acceptance of the Company's products and the continuing development of its products, risks associated with manufacturing and distributing its products on a commercial scale, risks associated with entering the human diagnostic market on a larger scale, risks involved in carrying of inventory, risks from unexpected problems or delays in the Company's manufacturing facility, risks associated with the ability to attract and retain competent sales personnel, general market conditions, competition, risks and uncertainties related to its ability to raise capital in order to fund its operations and other risks detailed from time to time in ABAXIS' periodic reports filed with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statement was made. ABAXIS does not undertake and specifically disclaims any obligation to update any forward-looking statements. DATASOURCE: ABAXIS, Inc. CONTACT: Clint Severson, Chief Executive Officer of ABAXIS, Inc., +1-510-675-6500; or Joe Dorame or Joe Diaz, +1-480-675-0400, both of RCG Capital Markets Group for ABAXIS, Inc. Web site: http://www.abaxis.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

SBIO ALPS Medical Breakthroughs ETF